$3.31 Billion in Sales Expected for Henry Schein, Inc. (HSIC) This Quarter

Equities analysts predict that Henry Schein, Inc. (NASDAQ:HSIC) will report $3.31 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have issued estimates for Henry Schein’s earnings. The highest sales estimate is $3.36 billion and the lowest is $3.21 billion. Henry Schein reported sales of $3.12 billion during the same quarter last year, which would suggest a positive year over year growth rate of 6.1%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 20th.

On average, analysts expect that Henry Schein will report full year sales of $3.31 billion for the current fiscal year, with estimates ranging from $12.29 billion to $12.54 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $13.20 billion per share, with estimates ranging from $12.99 billion to $13.36 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Henry Schein.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.87 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.03). The company had revenue of $3.16 billion during the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a net margin of 4.52% and a return on equity of 19.71%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.84 EPS.

A number of brokerages have recently commented on HSIC. Piper Jaffray Companies raised shares of Henry Schein from a “neutral” rating to an “overweight” rating in a research note on Friday, September 15th. Stephens began coverage on shares of Henry Schein in a research note on Tuesday, November 28th. They issued an “equal weight” rating and a $76.00 target price on the stock. Royal Bank of Canada began coverage on shares of Henry Schein in a research note on Tuesday, September 19th. They issued a “sector perform” rating and a $91.00 target price on the stock. TheStreet downgraded shares of Henry Schein from a “b” rating to a “c+” rating in a research note on Monday, November 6th. Finally, Stifel Nicolaus cut their target price on shares of Henry Schein from $89.00 to $77.00 and set a “hold” rating on the stock in a research note on Tuesday, November 7th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $87.79.

Shares of Henry Schein (NASDAQ:HSIC) traded down $0.01 during mid-day trading on Friday, hitting $68.69. 1,311,100 shares of the stock were exchanged, compared to its average volume of 1,247,927. Henry Schein has a fifty-two week low of $65.28 and a fifty-two week high of $93.50. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.86 and a current ratio of 1.55. The stock has a market cap of $11,030.00, a P/E ratio of 19.27, a PEG ratio of 1.93 and a beta of 0.99.

Henry Schein announced that its board has authorized a stock buyback program on Monday, September 18th that authorizes the company to repurchase $400.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 6.3% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

In other news, Director Barry J. Alperin sold 5,796 shares of Henry Schein stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $70.76, for a total value of $410,124.96. Following the completion of the transaction, the director now directly owns 48,172 shares of the company’s stock, valued at approximately $3,408,650.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.19% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. Parametric Portfolio Associates LLC boosted its stake in Henry Schein by 96.9% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 426,460 shares of the company’s stock valued at $34,965,000 after purchasing an additional 209,840 shares during the period. AXA boosted its stake in Henry Schein by 105.2% during the 3rd quarter. AXA now owns 101,768 shares of the company’s stock valued at $8,344,000 after purchasing an additional 52,184 shares during the period. Wagner Bowman Management Corp boosted its stake in Henry Schein by 100.0% during the 3rd quarter. Wagner Bowman Management Corp now owns 2,620 shares of the company’s stock valued at $214,000 after purchasing an additional 1,310 shares during the period. Shelton Capital Management boosted its stake in Henry Schein by 100.0% during the 3rd quarter. Shelton Capital Management now owns 12,450 shares of the company’s stock valued at $1,021,000 after purchasing an additional 6,225 shares during the period. Finally, Visionary Asset Management Inc. acquired a new position in Henry Schein during the 3rd quarter valued at about $208,000. 91.75% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://weekherald.com/2017/12/15/3-31-billion-in-sales-expected-for-henry-schein-inc-hsic-this-quarter.html.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply